ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
NME1	4830	8519661	-	-	-	-	-	2 (Leiomysarcoma ); 2 (myometrium); 2 (uterine cervix)	36 to 80	57	Kitasato University Hospital	I (n=13); II (n=4); III (n=9)	1 (n=15); 2 (n=5); 3 (n=8)	[1] The staining intensity for this protein is significantly stronger in well-differentiated adenocarcinomas (G1) than in those moderately differentiated (G2) (P < 0.05). nm23-H1 protein is shown by immunoblotting to be present at significantly higher levels in G1 than in G2 tumours (P < 0.05). [2] The high expression of nm23-H1 is positively correlated with histological differentiation.	Expression of nm23-H1 and nm23-H2 protein in endometrial carcinoma.	British Journal of Cancer	72(6):1469-73	1995
NME1	4830	20599259	-	Polymorphism	-	-	-	-	-	58.2 (patient); 56.2 (control)	Department of Obstetrics and Gynecology; Taichung Veterans General Hospital and Chung Shan Medical University Hospital; Taiwan.	I (n=66); II (n=13); III (n=10); IV (n=2)	-	[1] Heterozygous genotypes TC in rs16949649 and CT in rs2302254 of nm23-H1 promoter are potential susceptibility factors for endometrial cancer. [2] A trend of increased risk (OR: 26.67; P=0.01) of advanced stage endometrial cancer (stage III-IV) was observed in patients with TT genotype as compared to those with CC genotype in rs2302254.	Significant association of genetic polymorphism of human nonmetastatic clone 23 type 1 gene with an increased risk of endometrial cancer	Gynecologic Oncology	119(1):70-5	2010